Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × palbociclib × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 49 Sarcoma 6 Squamous Cell Carcinoma of Head and Neck 5 Neoplasms 5 Neoplasm Metastasis 5 Sarcoma, Ewing 4 Ovarian Neoplasms 4 Lymphoma, Non-Hodgkin 4 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Osteosarcoma 3 Neuroblastoma 3 Multiple Myeloma 3 Medulloblastoma 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Prostatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Lymphoma 2 Liposarcoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Head and Neck Neoplasms 2 Glioma 2 Estrogen Receptor-positive Breast Cancer 2 Ependymoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Chordoma 2 Carcinoma, Squamous Cell 2

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 fludarabine 4 Azacitidine 4 venetoclax 3 fludarabine phosphate 3 Cytarabine 3 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 talquetamab 1 selinexor 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2025-03-11

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡